Elevated pressure enhanced TRAIL-induced apoptosis in hepatocellular carcinoma cells via ERK1/2-inactivation

References

1. Ashkenazi, A., Pai, R.C., Fong, S., Leung, S., Lawrence, D.A., Marsters, S.A., Blackie, C., Chang, L., McMurtrey, A.E., Hebert, A., DeForge, L., Koumenis, I.L., Lewis, D., Harris, L., Bussiere, J., Koeppen, H., Shahrokh, Z. and Schwall, R.H. Safety and antitumor activity of recombinant soluble Apo2 ligand. J. Clin. Invest. 104 (1999) 155-216.Search in Google Scholar

2. Walczak, H., Miller, R.E., Ariail, K., Gliniak, B., Griffith, T.S., Kubin, M., Chin, W., Jones, J., Woodward, A., Le, T., Smith, C., Smolak, P., Goodwin, R.G., Rauch, C.T., Schuh, J.C. and Lynch, D.H. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat. Med. 5 (1999) 157-219.Search in Google Scholar

3. Plummer, R., Attard, G., Pacey, S., Li, L., Razak, A., Perrett, R., Barrett, M., Judson, I., Kaye, S., Fox, N.L., Halpern, W., Corey, A., Calvert, H. and de Bono, J. Phase 1 and pharmacokinetic study of lexatumumab in patients with advanced cancers. Clin. Cancer Res. 13 (2007) 6187-6280.Search in Google Scholar

4. Trarbach, T., Moehler, M., Heinemann, V., Kohne, C.H., Przyborek, M., Schulz, C., Sneller, V., Gallant, G. and Kanzler, S. Phase II trial of mapatumumab, a fully human agonistic monoclonal antibody that targets and activates the tumour necrosis factor apoptosis-inducing ligand receptor-1 (TRAIL-R1), in patients with refractory colorectal cancer. Br. J. Cancer 102 (2010) 506-517.Search in Google Scholar

5. Greco, F.A., Bonomi, P., Crawford, J., Kelly, K., Oh, Y., Halpern, W., Lo, L., Gallant, G. and Klein, J. Phase 2 study of mapatumumab, a fully human agonistic monoclonal antibody which targets and activates the RAIL receptor-1, in patients with advanced non-small cell lung cancer. Lung Cancer 61 (2008) 82-171.Search in Google Scholar

6. Hwang, M.K., Ryu, B.J. and Kim, S.H. AW00179 potentiates TRAILmediated death of human lung cancer H1299 cells through ROS-JNK-c-Junmediated upregulation of DR5 and downregulation of anti-apoptotic molecules. Amino Acids 43 (2012) 1679-1765.Search in Google Scholar

7. Hellwig, C.T. and Rehm, M. TRAIL signaling and synergy mechanisms used in TRAIL-based combination therapies. Mol. Cancer Ther. 11 (2012) 3-15.Search in Google Scholar

8. Oh, S., Kim, Y., Kim, J., Kwon, D. and Lee, E. Elevated pressure, a novel cancer therapeutic tool for sensitizing cisplatin-mediated apoptosis in A549. Biochem. Biophys. Res. Commun. 399 (2010) 91-97.Search in Google Scholar

9. Oh, S., Kwon, D., Lee, H.J., Kim, J. and Lee, E. Role of elevated pressure in TRAIL-induced apoptosis in human lung carcinoma cells. Apoptosis 15 (2010) 1517-1544.Search in Google Scholar

10. Oh, S., Lee, E., Lee, J., Lim, Y., Kim, J. and Woo, S. Comparison of the effects of 40% oxygen and two atmospheric absolute air pressure conditions on stress-induced premature senescence of normal human diploid fibroblasts. Cell Stress Chaperones 13 (2008) 447-504.Search in Google Scholar

11. Rubin, J., Murphy, T.C., Fan, X., Goldschmidt, M. and Taylor, W.R. Activation of extracellular signal-regulated kinase is involved in mechanical strain inhibition of RANKL expression in bone stromal cells. J. Bone Miner. Res. 17 (2002) 1452-1511.Search in Google Scholar

12. Clark, E.A. and Brugge, J.S. Integrins and signal transduction pathways: the road taken. Science 268 (1995) 233-241.Search in Google Scholar

13. Giancotti, F.G. and Ruoslahti, E. Integrin signaling. Science 285 (1999) 1028-1059.Search in Google Scholar

14. Chen, X., Thakkar, H., Tyan, F., Gim, S., Robinson, H., Lee, C., Pandey, S.K., Nwokorie, C., Onwudiwe, N. and Srivastava, R.K. Constitutively active Akt is an important regulator of TRAIL sensitivity in prostate cancer. Oncogene 20 (2001) 6073-6155.Search in Google Scholar

15. Dida, F., Li, Y., Iwao, A., Deguchi, T., Azuma, E. and Komada, Y. Resistance to TRAIL-induced apoptosis caused by constitutional phosphorylation of Akt and PTEN in acute lymphoblastic leukemia cells. Exp. Hematol. 36 (2008) 1343-1395.Search in Google Scholar

16. Gibson, E.M., Henson, E.S., Haney, N., Villanueva, J. and Gibson, S.B. Epidermal growth factor protects epithelial-derived cells from tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by inhibiting cytochrome c release. Cancer Res. 62 (2002) 488-583.Search in Google Scholar

17. Bonni, A., Brunet, A., West, A.E., Datta, S.R., Takasu, M.A. and Greenberg, M.E. Cell survival promoted by the Ras-MAPK signaling pathway by transcription-dependent and -independent mechanisms. Science 286 (1999) 1358-1419.Search in Google Scholar

18. Goncharenko-Khaider, N., Lane, D., Matte, I., Rancourt, C. and Piche, A. The inhibition of Bid expression by Akt leads to resistance to TRAILinduced apoptosis in ovarian cancer cells. Oncogene 29 (2010) 5523-5558.Search in Google Scholar

19. Johnstone, R.W., Frew, A.J. and Smyth, M.J. The TRAIL apoptotic pathway in cancer onset, progression and therapy. Nat. Rev. Cancer 8 (2008) 782-179.10.1038/nrc2465Search in Google Scholar PubMed

20. Kim, M.O., Moon, D.O., Kang, C.H., Kwon, T.K., Choi, Y.H. and Kim, G.Y. beta-Ionone enhances TRAIL-induced apoptosis in hepatocellular carcinoma cells through Sp1-dependent upregulation of DR5 and downregulation of NF-kappaB activity. Mol. Cancer Ther. 9 (2010) 833-875.Search in Google Scholar

21. Shankar, E., Krishnamurthy, S., Paranandi, R. and Basu, A. PKCepsilon induces Bcl-2 by activating CREB. Int. J. Oncol. 36 (2010) 883-890.Search in Google Scholar

22. Wiesenauer, C.A., Yip-Schneider, M.T., Wang, Y. and Schmidt, C.M. Multiple anticancer effects of blocking MEK-ERK signaling in hepatocellular carcinoma. J. Am. Coll. Surg. 198 (2004) 410-430.Search in Google Scholar

23. Li, Y., Wang, H., Wang, Z., Makhija, S., Buchsbaum, D., LoBuglio, A., Kimberly, R. and Zhou, T. Inducible resistance of tumor cells to tumor necrosis factor-related apoptosis-inducing ligand receptor 2-mediated apoptosis by generation of a blockade at the death domain function. Cancer Res. 66 (2006) 8520-8527.Search in Google Scholar

24. Johnson, T.R., Stone, K., Nikrad, M., Yeh, T., Zong, W.X., Thompson, C.B., Nesterov, A. and Kraft, A.S. The proteasome inhibitor PS-341 overcomes TRAIL resistance in Bax and caspase 9-negative or Bcl-xL overexpressing cells. Oncogene 22 (2003) 4953-5015.Search in Google Scholar

25. Koschny, R., Ganten, T.M., Sykora, J., Haas, T.L., Sprick, M.R., Kolb, A., Stremmel, W. and Walczak, H. TRAIL/bortezomib cotreatment is potentially hepatotoxic but induces cancer-specific apoptosis within a therapeutic window. Hepatology 45 (2007) 649-706.Search in Google Scholar

26. Liu, X., Yue, P,. Chen, S., Hu, L., Lonial, S., Khuri, F.R. and Sun, S.Y. The proteasome inhibitor PS-341 (bortezomib) upregulates DR5 expression leading to induction of apoptosis and enhancement of TRAIL-induced apoptosis despite upregulation of c-FLIP and survivin expression in human NSCLC cells. Cancer Res. 67 (2007) 4981-4988.Search in Google Scholar

27. Lundqvist, A., Abrams, S.I., Schrump, D.S., Alvarez, G., Suffredini, D., Berg, M. and Childs, R. Bortezomib and depsipeptide sensitize tumors to tumor necrosis factor-related apoptosis-inducing ligand: a novel method to potentiate natural killer cell tumor cytotoxicity. Cancer Res. 66 (2006) 7317-7341.Search in Google Scholar

28. Saulle, E., Petronelli, A., Pasquini, L., Petrucci, E., Mariani, G., Biffoni, M., Ferretti, G., Scambia, G., Benedetti-Panici, P., Cognetti, F., Humphreys, R., Peschle, C. and Testa, U. Proteasome inhibitors sensitize ovarian cancer cells to TRAIL induced apoptosis. Apoptosis 12 (2007) 635-689.Search in Google Scholar

29. Hanahan, D. and Weinberg, R.A. The hallmarks of cancer. Cell 100 (2000) 57-126.Search in Google Scholar

30. Zhang, L. and Fang, B. Mechanisms of resistance to TRAIL-induced apoptosis in cancer. Cancer Gene Ther. 12 (2005) 228-264.Search in Google Scholar

31. Frese, S., Pirnia, F., Miescher, D., Krajewski, S., Borner, M.M., Reed, J.C. and Schmid, R.A. PG490-mediated sensitization of lung cancer cells to Apo2L/TRAIL-induced apoptosis requires activation of ERK2. Oncogene 22 (2003) 5427-5461.Search in Google Scholar

32. Kim, Y.H., Lee, D.H., Jeong, J.H., Guo, Z.S. and Lee, Y.J. Quercetin augments TRAIL-induced apoptotic death: involvement of the ERK signal transduction pathway. Biochem. Pharmacol. 75 (2008) 1946-2003.Search in Google Scholar

33. Lunghi, P., Giuliani, N., Mazzera, L., Lombardi, G., Ricca, M., Corradi, A., Cantoni, A.M., Salvatore, L., Riccioni, R., Costanzo, A., Testa, U., Levrero, M., Rizzoli, V. and Bonati, A. Targeting MEK/MAPK signal transduction module potentiates ATO-induced apoptosis in multiple myeloma cells through multiple signaling pathways. Blood 112 (2008) 2450-2511.Search in Google Scholar

34. Ganten, T.M., Koschny, R., Haas, T.L., Sykora, J., Li-Weber, M., Herzer, K. and Walczak, H. Proteasome inhibition sensitizes hepatocellular carcinoma cells, but not human hepatocytes, to TRAIL. Hepatology 42 (2005) 588-684. 10.1002/hep.20807Search in Google Scholar PubMed